QIAGEN(US:QGEN) ZACKSยท2025-06-20 14:51Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2][3] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum, with A being the highest score indicating better chances of outperforming [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Aims to capitalize on price trends by evaluating recent price changes and earnings estimate revisions [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth forecasts, and momentum [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to simplify stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9][10] Company Spotlight: Qiagen (QGEN) - Qiagen N.V. is a leading provider of technologies for nucleic acid handling, with a diverse portfolio of over 500 proprietary products [11] - Qiagen holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a projected year-over-year earnings growth of 7.3% for the current fiscal year [12] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $2.34 per share, and an average earnings surprise of 4.9% [12][13]